70774-25-3 Usage
Uses
Used in Anticancer Applications:
Leurubicin is used as an antineoplastic agent for the treatment of various types of cancer. It is particularly effective against solid malignancies, such as liver, breast, lung, pancreatic, colorectal, and ovarian cancers. Leurubicin works by being selectively taken up by cancer cells, where it is then converted into the active form, Doxorubicin. This conversion allows for the targeted delivery of the chemotherapeutic agent, reducing damage to healthy cells and minimizing side effects.
Used in Drug Delivery Systems:
Leurubicin is also used in the development of novel drug delivery systems to enhance the efficacy and bioavailability of Doxorubicin. These systems aim to improve the delivery of the active drug to cancer cells, while minimizing its exposure to healthy cells. By employing various organic and metallic nanoparticles as carriers for Leurubicin, researchers can optimize the drug's pharmacokinetics and therapeutic outcomes, leading to more effective cancer treatments with fewer side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 70774-25-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,0,7,7 and 4 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 70774-25:
(7*7)+(6*0)+(5*7)+(4*7)+(3*4)+(2*2)+(1*5)=133
133 % 10 = 3
So 70774-25-3 is a valid CAS Registry Number.
InChI:InChI=1/C33H40N2O12/c1-13(2)8-17(34)32(43)35-18-9-22(46-14(3)27(18)38)47-20-11-33(44,21(37)12-36)10-16-24(20)31(42)26-25(29(16)40)28(39)15-6-5-7-19(45-4)23(15)30(26)41/h5-7,13-14,17-18,20,22,27,36,38,40,42,44H,8-12,34H2,1-4H3,(H,35,43)/t14-,17-,18-,20-,22-,27+,33-/m0/s1
70774-25-3Relevant academic research and scientific papers
Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs
Jain, Mohit,Harburn, J. Jonathan,Gill, Jason H.,Loadman, Paul M.,Falconer, Robert A.,Mooney, Caitlin A.,Cobb, Steven L.,Berry, David J.
supporting information, p. 4496 - 4502 (2017/06/05)
Matrix metalloproteinases (MMPs) are central to cancer development and metastasis. They are highly active in the tumor environment and absent or inactive in normal tissues; therefore they represent viable targets for cancer drug discovery. In this study we evaluated in silico docking to develop MMP-subtype-selective tumor-activated prodrugs. Proof of principle for this therapeutic approach was demonstrated in vitro against an aggressive human glioma model, with involvement of MMPs confirmed using pharmacological inhibition.
